QED establishes subsidiary in India
11 May 2012 | News
QED Clinical Services, a global clinical research organization (CRO), has announced the creation of a wholly owned subsidiary in India called QED Clinical Services India. The new entity would be based out of Ahmedabad and will be led by Ali Saijad Bohra as its country head and director of operations.
QED India, in addition to the conducting clinical trials, will act as a hub for QED's Asia-Pacific operations to enhance control and oversight of its local partners across the wider Asia-Pacific region. “India and the Asia Pacific region will continue to have focus and will remain key markets for the drug development activities for biopharmaceutical companies on account of a variety of benefits. With our in-depth experience and knowledge of the region, we are committed to providing customized, cost-efficient and high quality services to both global as well as local clients,� said Bohra.
SIRO to bolster operation in Europe
SIRO Clinpharm, a leading full service clinical research organization, plans to further strengthen its operations in Europe in the areas of biostatistics, data management and clinical trials. SIRO Clinpharm Germany at Offenbach in Germany will act as a hub for this purpose.
“Our European business has been operational for 19 years and we have been serving customers for many years with great success,� said Gopakumar Menon, chief executive officer, SIRO Clinpharm. “My vision is to leverage this experience and expertise, coupled with SIRO's geographic reach in the Eastern European and Asian region, and build and deliver innovative solutions to global biopharma clients.�
“With a dynamic regulatory landscape and the continued pressure on pricing and dwindling pipelines, the bottom line for today's European biopharma is squeezed like never before,� said Timothy Scane, senior director business development, SIRO Clinpharm Germany.
Jubilant secures major contracts
Jubilant HollisterStier, a subsidiary of Jubilant Life Sciences, announced that its contract manufacturing and services division has recently secured contracts with four innovator life science companies for the commercial manufacturing of sterile parenteral products for sale in the US and Europe. These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications. The deal is valued over $90 million and is contracted for five-year term. Commercial transfer to the Jubilant HollisterStier manufacturing facility has commenced for all contracts.
Commenting on the multi-million deal, Shyam S Bhartia, chairman and managing director, and Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences jointly said, “We are pleased with signing of these long term contracts with innovator pharma companies to serve the regulated markets of US and Europe. This is a direct result of our increased business development efforts leading to higher utilization of our existing capacity.�
Quintiles wins best CRO award
Global biopharmaceutical services company Quintiles has been named the Best Clinical Research Organization (CRO) at Vaccine Industry Excellence (ViE) Awards 2012.
“This is a great honor to be recognized as the best CRO at the World Vaccine Congress,� said Ellen Vigdorth, VP allergy, respiratory, infectious diseases and vaccines, Quintiles. “It is a huge achievement and underscores our commitment to the development of quality vaccines and anti-infective products.� This award comes shortly after Quintiles was named, for the second year running, the 2012 Asia Pacific CRO of the Year at the BioPharma Convention Awards.
NCS expands its operations
Norwich Clinical Services (NCS) announced a significant expansion in its clinical research capabilities. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of phase I–III clinical trials including pharmacokinetics in healthy volunteers, bioavailability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
“Utilizing proven technologies and this new, modern clinical facility, NCS is now able to offer functional expertise and therapeutic experience with reliability that will create cost and time efficiency for customers. We are proud to be opening this new clinical trial facility with full regulatory approvals from the Drugs Controller General of India,� stated Saral Thangam, managing director, NCS.
QED India, in addition to the conducting clinical trials, will act as a hub for QED's Asia-Pacific operations to enhance control and oversight of its local partners across the wider Asia-Pacific region. “India and the Asia Pacific region will continue to have focus and will remain key markets for the drug development activities for biopharmaceutical companies on account of a variety of benefits. With our in-depth experience and knowledge of the region, we are committed to providing customized, cost-efficient and high quality services to both global as well as local clients,� said Bohra.
SIRO to bolster operation in Europe
SIRO Clinpharm, a leading full service clinical research organization, plans to further strengthen its operations in Europe in the areas of biostatistics, data management and clinical trials. SIRO Clinpharm Germany at Offenbach in Germany will act as a hub for this purpose.
“Our European business has been operational for 19 years and we have been serving customers for many years with great success,� said Gopakumar Menon, chief executive officer, SIRO Clinpharm. “My vision is to leverage this experience and expertise, coupled with SIRO's geographic reach in the Eastern European and Asian region, and build and deliver innovative solutions to global biopharma clients.�
“With a dynamic regulatory landscape and the continued pressure on pricing and dwindling pipelines, the bottom line for today's European biopharma is squeezed like never before,� said Timothy Scane, senior director business development, SIRO Clinpharm Germany.
Jubilant secures major contracts
Jubilant HollisterStier, a subsidiary of Jubilant Life Sciences, announced that its contract manufacturing and services division has recently secured contracts with four innovator life science companies for the commercial manufacturing of sterile parenteral products for sale in the US and Europe. These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications. The deal is valued over $90 million and is contracted for five-year term. Commercial transfer to the Jubilant HollisterStier manufacturing facility has commenced for all contracts.
Commenting on the multi-million deal, Shyam S Bhartia, chairman and managing director, and Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences jointly said, “We are pleased with signing of these long term contracts with innovator pharma companies to serve the regulated markets of US and Europe. This is a direct result of our increased business development efforts leading to higher utilization of our existing capacity.�
Quintiles wins best CRO award
Global biopharmaceutical services company Quintiles has been named the Best Clinical Research Organization (CRO) at Vaccine Industry Excellence (ViE) Awards 2012.
“This is a great honor to be recognized as the best CRO at the World Vaccine Congress,� said Ellen Vigdorth, VP allergy, respiratory, infectious diseases and vaccines, Quintiles. “It is a huge achievement and underscores our commitment to the development of quality vaccines and anti-infective products.� This award comes shortly after Quintiles was named, for the second year running, the 2012 Asia Pacific CRO of the Year at the BioPharma Convention Awards.
NCS expands its operations
Norwich Clinical Services (NCS) announced a significant expansion in its clinical research capabilities. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of phase I–III clinical trials including pharmacokinetics in healthy volunteers, bioavailability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
“Utilizing proven technologies and this new, modern clinical facility, NCS is now able to offer functional expertise and therapeutic experience with reliability that will create cost and time efficiency for customers. We are proud to be opening this new clinical trial facility with full regulatory approvals from the Drugs Controller General of India,� stated Saral Thangam, managing director, NCS.
